{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:14:02Z","timestamp":1791821642342,"version":"4.3.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:00:00Z","timestamp":1636588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:00:00Z","timestamp":1636588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s12029-021-00745-4","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:02:24Z","timestamp":1636588944000},"page":"1206-1210","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Hepatitis B Before and After Hepatocellular Carcinoma"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9415-147X","authenticated-orcid":false,"given":"Murat","family":"Harputluoglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian I.","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,11]]},"reference":[{"key":"745_CR1","unstructured":"Asafo-Agyei KO, Samant H. Hepatocellular carcinoma. Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2021 PMID: 32644603."},{"key":"745_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.601710.PMID:33330100;PMCID:PMC7734960","volume":"30","author":"D Suresh","year":"2020","unstructured":"Suresh D, Srinivas AN, Kumar DP. Etiology of hepatocellular carcinoma: special focus on fatty liver disease. Front Oncol. 2020;30: 601710. https:\/\/doi.org\/10.3389\/fonc.2020.601710.PMID:33330100;PMCID:PMC7734960.","journal-title":"Front Oncol"},{"key":"745_CR3","doi-asserted-by":"publisher","first-page":"7027169","DOI":"10.1155\/2020\/7027169.PMID:32626758;PMCID:PMC7305551","volume":"2020","author":"S Madihi","year":"2020","unstructured":"Madihi S, Syed H, Lazar F, Zyad A, Benani A. A systematic review of the current hepatitis B viral infection and hepatocellular carcinoma situation in Mediterranean countries. Biomed Res Int. 2020;2020:7027169. https:\/\/doi.org\/10.1155\/2020\/7027169.PMID:32626758;PMCID:PMC7305551.","journal-title":"Biomed Res Int"},{"key":"745_CR4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/CEJ.0000000000000428.PMID:29489473;PMCID:PMC5876122","volume":"27","author":"A Baecker","year":"2018","unstructured":"Baecker A, Liu X, La Vecchia C, Zhang ZF. Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors. Eur J Cancer Prev. 2018;27:205\u201312. https:\/\/doi.org\/10.1097\/CEJ.0000000000000428.PMID:29489473;PMCID:PMC5876122.","journal-title":"Eur J Cancer Prev"},{"key":"745_CR5","doi-asserted-by":"publisher","unstructured":"Varbobitis I, Papatheodoridis GV.\u00a0The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy. Clin Mol Hepatol. 2016;22:319\u2013326.\u00a0https:\/\/doi.org\/10.3350\/cmh.2016.0045. Epub 2016 Sep 25. PMID: 27729632; PMCID: PMC5066383.","DOI":"10.3350\/cmh.2016.0045"},{"key":"745_CR6","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","volume":"391","author":"A Forner","year":"2018","unstructured":"Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301\u201314. https:\/\/doi.org\/10.1016\/S0140-6736(18)30010-2 (Epub 2018 Jan 5 PMID: 29307467).","journal-title":"Lancet"},{"key":"745_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/apt.14683","volume":"48","author":"CL Lin","year":"2018","unstructured":"Lin CL, Kao JH. Review article: the prevention of hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther. 2018;48:5\u201314. https:\/\/doi.org\/10.1111\/apt.14683 (Epub 2018 May 3 PMID: 29722445).","journal-title":"Aliment Pharmacol Ther"},{"key":"745_CR8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1473-3099(02)00315-8","volume":"2","author":"JH Kao","year":"2002","unstructured":"Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis. 2002;2:395\u2013403.","journal-title":"Lancet Infect Dis"},{"key":"745_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/978-981-10-5765-6_2","volume":"1018","author":"Y Xie","year":"2017","unstructured":"Xie Y. Hepatitis B virus-associated hepatocellular carcinoma. Adv Exp Med Biol. 2017;1018:11\u201321. https:\/\/doi.org\/10.1007\/978-981-10-5765-6_2 (PMID: 29052129).","journal-title":"Adv Exp Med Biol"},{"key":"745_CR10","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1056\/NEJMoa013215","volume":"347","author":"Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, Chen PJ, Chen DS, Chen CJ. Taiwan Community-Based Cancer Screening Project Group","year":"2002","unstructured":"Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, Chen PJ, Chen DS, Chen CJ. Taiwan Community-Based Cancer Screening Project Group. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347:168\u201374.","journal-title":"N Engl J Med"},{"key":"745_CR11","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJM199706263362602","volume":"336","author":"MH Chang","year":"1997","unstructured":"Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Child Hepatoma Study Group. New England J Med. 1997;336:1855\u20139.","journal-title":"New England J Med"},{"key":"745_CR12","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jhep.2014.04.038","volume":"61","author":"AJ Greenup","year":"2014","unstructured":"Greenup AJ, Tan PK, Nguyen V, Glass A, Davison S, Chatterjee U, Holdaway S, Samarasinghe D, Jackson K, Locarnini SA, Levy MT. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol. 2014;61:502\u20137.","journal-title":"J Hepatol"},{"key":"745_CR13","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1056\/NEJMoa1508660","volume":"374","author":"Pan CQ, Duan Z, Dai E, Zhang S, Han G, Wang Y, Zhang H, Zou H, Zhu B, Zhao W, Jiang H, China Study Group for the Mother-to-Child Transmission of Hepatitis B","year":"2016","unstructured":"Pan CQ, Duan Z, Dai E, Zhang S, Han G, Wang Y, Zhang H, Zou H, Zhu B, Zhao W, Jiang H, China Study Group for the Mother-to-Child Transmission of Hepatitis B. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med. 2016;374:2324\u201334.","journal-title":"N Engl J Med"},{"key":"745_CR14","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800.PMID:29405329;PMCID:PMC5975958","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560\u201399. https:\/\/doi.org\/10.1002\/hep.29800.PMID:29405329;PMCID:PMC5975958.","journal-title":"Hepatology"},{"key":"745_CR15","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370\u201398. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.021 (Epub 2017 Apr 18 PMID: 28427875).","journal-title":"J Hepatol"},{"key":"745_CR16","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1097\/00006454-199305000-00037","volume":"12","author":"DP Greenberg","year":"1993","unstructured":"Greenberg DP. Pediatric experience with recombinant hepatitis B vaccines and relevant safety and immunogenicity studies. Pediatr Infect Dis J. 1993;12:438\u201345.","journal-title":"Pediatr Infect Dis J"},{"key":"745_CR17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jama.295.1.65","volume":"295","author":"Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH, Group R-HS","year":"2006","unstructured":"Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH, Group R-HS. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65\u201373.","journal-title":"JAMA"},{"key":"745_CR18","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1002\/hep.22884","volume":"49","author":"Chen CJ, Yang HI, Iloeje UH, Group R-HS","year":"2009","unstructured":"Chen CJ, Yang HI, Iloeje UH, Group R-HS. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology. 2009;49:S72\u201384.","journal-title":"Hepatology"},{"key":"745_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1200\/JCO.2007.13.2043","volume":"26","author":"HL Chan","year":"2008","unstructured":"Chan HL, Tse CH, Mo F, Koh J, Wong VW, Wong GL, Lam Chan S, Yeo W, Sung JJ, Mok TS. High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol. 2008;26:177\u201382.","journal-title":"J Clin Oncol"},{"key":"745_CR20","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/hep.25937","volume":"57","author":"CL Lai","year":"2013","unstructured":"Lai CL, Yuen MF. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology. 2013;57:399\u2013408.","journal-title":"Hepatology"},{"key":"745_CR21","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/liv.12057","volume":"33","author":"YF Liaw","year":"2013","unstructured":"Liaw YF. Impact of therapy on the outcome of chronic hepatitis B. Liver Int. 2013;33:111\u20135.","journal-title":"Liver Int"},{"key":"745_CR22","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1056\/NEJMoa033364","volume":"351","author":"YF Liaw","year":"2004","unstructured":"Liaw YF, Sung JJY, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521\u201331.","journal-title":"N Engl J Med"},{"key":"745_CR23","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.jhep.2015.01.002","volume":"62","author":"GV Papatheodoridis","year":"2015","unstructured":"Papatheodoridis GV, Chan HL, Hansen BE, Janssen HL, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol. 2015;62:956\u201367.","journal-title":"J Hepatol"},{"key":"745_CR24","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/hep.26180","volume":"58","author":"T Hosaka","year":"2013","unstructured":"Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013;58:98\u2013107.","journal-title":"Hepatology"},{"key":"745_CR25","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1111\/liv.13253","volume":"36","author":"TH Su","year":"2016","unstructured":"Su TH, Hu TH, Chen CY, et al. C-TEAM study group and the Taiwan Liver Diseases Consortium. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int. 2016;36:1755\u201364.","journal-title":"Liver Int"},{"key":"745_CR26","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1002\/cncr.29537","volume":"121","author":"WR Kim","year":"2015","unstructured":"Kim WR, Loomba R, Berg T, Aguilar Schall RE, Yee LJ, Dinh PV, Flaherty JF, Martins EB, Therneau TM, Jacobson I, Fung S, Gurel S, Buti M, Marcellin P. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer. 2015;121:3631\u20138. https:\/\/doi.org\/10.1002\/cncr.29537 (Epub 2015 Jul 15 PMID: 26177866).","journal-title":"Cancer"},{"key":"745_CR27","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1002\/hep.29320","volume":"66","author":"GV Papatheodoridis","year":"2017","unstructured":"Papatheodoridis GV, Idilman R, Dalekos GN, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology. 2017;66:1444\u201353.","journal-title":"Hepatology"},{"key":"745_CR28","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1186\/s12885-019-5735-9.PMID:31142283;PMCID:PMC6542001","volume":"19","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Zhou Y, Yang J, Hu K, Huang Y. The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis. BMC Cancer. 2019;19:511. https:\/\/doi.org\/10.1186\/s12885-019-5735-9.PMID:31142283;PMCID:PMC6542001.","journal-title":"BMC Cancer"},{"key":"745_CR29","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.cgh.2020.05.008","volume":"19","author":"WM Choi","year":"2021","unstructured":"Choi WM, Choi J, Lim YS. Effects of tenofovir vs entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021;19:246-258.e9. https:\/\/doi.org\/10.1016\/j.cgh.2020.05.008 (Epub 2020 May 11 PMID: 32407970).","journal-title":"Clin Gastroenterol Hepatol"},{"key":"745_CR30","doi-asserted-by":"publisher","unstructured":"Yip TC, Lai JC, Wong GL.\u00a0Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same? J Gastroenterol\u00a02020;55:1023\u20131036.\u00a0https:\/\/doi.org\/10.1007\/s00535-020-01726-3. Epub 2020 Sep 24. PMID: 32974760; PMCID: PMC7567686.","DOI":"10.1007\/s00535-020-01726-3"},{"key":"745_CR31","doi-asserted-by":"publisher","unstructured":"Tseng CH, Hsu YC, Chen TH, et al.\u00a0Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020;5:1039\u20131052.\u00a0https:\/\/doi.org\/10.1016\/S2468-1253(20)30249-1. Epub 2020 Sep 30. Erratum in: Lancet Gastroenterol Hepatol. 2021 Feb;6(2):e1. PMID: 33007228.","DOI":"10.1016\/S2468-1253(20)30249-1"},{"key":"745_CR32","doi-asserted-by":"publisher","unstructured":"Lee HW, Cho YY, Lee H, Lee JS, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK, Park SY.\u00a0Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B. J Viral Hepat\u00a02021;26.\u00a0https:\/\/doi.org\/10.1111\/jvh.13601. Epub ahead of print. PMID: 34435412.","DOI":"10.1111\/jvh.13601"},{"key":"745_CR33","doi-asserted-by":"publisher","unstructured":"Lee HW, Cho YY, Lee H, Lee JS, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK, Park SY.\u00a0Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B. Hepatol Int 2021;16.\u00a0https:\/\/doi.org\/10.1007\/s12072-021-10234-2. Epub ahead of print. PMID: 34402025.","DOI":"10.1007\/s12072-021-10234-2"},{"key":"745_CR34","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","volume":"70","author":"TC-F Yip","year":"2019","unstructured":"Yip TC-F, Wong GL-H, Chan HL-Y, et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. J Hepatol. 2019;70:361\u201370.","journal-title":"J Hepatol"},{"key":"745_CR35","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","volume":"63","author":"G Kim","year":"2014","unstructured":"Kim G, Lim Y, An J, et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut. 2014;63:1325\u201332.","journal-title":"Gut"},{"key":"745_CR36","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jfma.2013.02.001","volume":"112","author":"CL Lin","year":"2013","unstructured":"Lin CL, Kao JH. Hepatitis B viral factors and treatment responses in chronic hepatitis B. J Formos Med Assoc. 2013;112:302\u201311.","journal-title":"J Formos Med Assoc"},{"key":"745_CR37","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/infdis\/jiv547","volume":"213","author":"KH Liang","year":"2016","unstructured":"Liang KH, Hsu CW, Chang ML, Chen YC, Lai MW, Yeh CT. Peginterferon is superior to nucleos(t)ide analogues for prevention of hepatocellular carcinoma in chronic hepatitis B. J Infect Dis. 2016;213:966\u201374.","journal-title":"J Infect Dis"},{"key":"745_CR38","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1080\/14712598.2018.1518423","volume":"18","author":"P Ren","year":"2018","unstructured":"Ren P, Cao Z, Mo R, et al. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk. Expert Opin Biol Ther. 2018;18:1085\u201394. https:\/\/doi.org\/10.1080\/14712598.2018.1518423 (Epub 2018 Sep 13 PMID: 30182763).","journal-title":"Expert Opin Biol Ther"},{"key":"745_CR39","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11684-021-0848-3","volume":"15","author":"W Zhang","year":"2021","unstructured":"Zhang W, Zhang B, Chen XP. Adjuvant treatment strategy after curative resection for hepatocellular carcinoma. Front Med. 2021;15:155\u201369. https:\/\/doi.org\/10.1007\/s11684-021-0848-3 (Epub 2021 Mar 23 PMID: 33754281).","journal-title":"Front Med"},{"key":"745_CR40","doi-asserted-by":"publisher","unstructured":"Li MR, Chen GH, Cai CJ, Wang GY, Zhao H.\u00a0High hepatitis B virus DNA level in serum before liver transplantation increases the risk of hepatocellular carcinoma recurrence. Digestion. 2011;84:134\u2013141. PMID: 21502763.\u00a0https:\/\/doi.org\/10.1159\/000324197","DOI":"10.1159\/000324197"},{"key":"745_CR41","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1111\/j.1440-1746.2006.04707.x","volume":"22","author":"T Kuzuya","year":"2007","unstructured":"Kuzuya T, Katano Y, Kumada T, et al. (2007) Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol Hepatol. 2007;22:1929\u201335.","journal-title":"J Gastroenterol Hepatol"},{"key":"745_CR42","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1245\/s10434-009-0694-z","volume":"17","author":"N Li","year":"2010","unstructured":"Li N, Lai EC, Shi J, et al. A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection. Ann Surg Oncol. 2010;17:179\u201385.","journal-title":"Ann Surg Oncol"},{"key":"745_CR43","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1007\/s10620-018-5252-8","volume":"63","author":"G Zhang","year":"2018","unstructured":"Zhang G, Yu X, Liu P, Huang X, Jiang X. Efficacy of nucleoside analogs for chronic hepatitis B virus-related hepatocellular carcinoma after curative treatment: a meta-analysis. Dig Dis Sci. 2018;63:3207\u201319.","journal-title":"Dig Dis Sci"},{"key":"745_CR44","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.2147\/OTT.S150281","volume":"10","author":"XX Chen","year":"2017","unstructured":"Chen XX, Cheng JW, Huang A, Zhang X, Wang J, Fan J, Zhou J, Yang XR. The effect of antiviral therapy on patients with hepatitis B virus-related hepatocellular carcinoma after curative resection: a systematic review and meta-analysis. OncoTargets Ther. 2017;10:5363\u201375.","journal-title":"OncoTargets Ther"},{"key":"745_CR45","first-page":"5234969","volume":"2016","author":"P Yuan","year":"2016","unstructured":"Yuan P, Chen P, Qian Y. Evaluation of antiviral therapy performed after curative therapy in patients with HBV-related hepatocellular carcinoma: an updated meta-analysis. Can J Gastroenterol Hepatol. 2016;2016:5234969.","journal-title":"Can J Gastroenterol Hepatol"},{"key":"745_CR46","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/hepr.12584","volume":"46","author":"GM Liu","year":"2016","unstructured":"Liu GM, Huang XY, Shen SL, Hu WJ, Peng BG. Adjuvant antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis. Hepatol Res. 2016;46:100\u201310.","journal-title":"Hepatol Res"},{"key":"745_CR47","doi-asserted-by":"publisher","unstructured":"Wong JS, Wong GL, Tsoi KK, Wong VW, Cheung SY, Chong CN, Wong J, Lee KF, Lai PB, Chan HL. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther. 2011;33:1104\u20131112. [PMID: 21488914: https:\/\/doi.org\/10.1111\/j.1365-2036.2011.04634.x]","DOI":"10.1111\/j.1365-2036.2011.04634.x"},{"key":"745_CR48","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1007\/s10620-019-05543-4","volume":"64","author":"ZW Jian","year":"2019","unstructured":"Jian ZW, Wu XW, Chen ZX, Wang JC, Peng JY, Lao XM. Effect of nucleos(t)ide analogs on patients with intermediate and advanced hepatitis B virus-related hepatocellular carcinoma. Dig Dis Sci. 2019;64:2187\u201398. https:\/\/doi.org\/10.1007\/s10620-019-05543-4 (Epub 2019 Feb 28 PMID: 30815819).","journal-title":"Dig Dis Sci"},{"key":"745_CR49","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/hep.31289","volume":"73","author":"J Choi","year":"2021","unstructured":"Choi J, Jo C, Lim YS. Tenofovir versus entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection. Hepatology. 2021;73:661\u201373. https:\/\/doi.org\/10.1002\/hep.31289 (Epub 2020 Nov 2 PMID: 32324905).","journal-title":"Hepatology"},{"key":"745_CR50","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s11605-020-04633-3","volume":"25","author":"X Zhang","year":"2021","unstructured":"Zhang X, Li C, Wen T, Yan L, Yang J, Tang H, Lu C. The different effects of nucleotide and nucleoside analogues on the prognosis of HBV-related HCC after curative resection. J Gastrointest Surg. 2021;25:1419\u201329. https:\/\/doi.org\/10.1007\/s11605-020-04633-3 (Epub 2020 May 14 PMID: 32410175).","journal-title":"J Gastrointest Surg"},{"key":"745_CR51","doi-asserted-by":"publisher","unstructured":"Huang G, Yang Y, Shen F, Pan ZY, Fu SY, Lau WY, et al.\u00a0Early viral suppression predicts good postoperative survivals in patients with hepatocellular carcinoma with a high baseline HBV-DNA load. Annals of Surgical Oncology. 2013;20:1482\u20131490. https:\/\/doi.org\/10.1245\/s10434-012-2803-7.","DOI":"10.1245\/s10434-012-2803-7"},{"key":"745_CR52","doi-asserted-by":"publisher","unstructured":"Lee JH, Kim BK, Park SY, Tak WY, Park JY, Kim DY, et al.\u00a0The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma. Eur J Intern Med. 2021;89:48\u201355.\u00a0https:\/\/doi.org\/10.1016\/j.ejim.2021.02.019. Epub 2021 Mar 31. PMID: 33810942.","DOI":"10.1016\/j.ejim.2021.02.019"},{"key":"745_CR53","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1111\/j.1440-1746.2009.05863.x","volume":"24","author":"M Li","year":"2009","unstructured":"Li M, Lu C, Cheng J, Zhang J, Cao C, Xu J, Xu J, Pan H, Zhong B, Tucker S, Wang D. Combination therapy with transarterial chemoembolization and interferon-alpha compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma. J Gastroenterol Hepatol. 2009;24:1437\u201344. https:\/\/doi.org\/10.1111\/j.1440-1746.2009.05863.x (Epub 2009 May 28 PMID: 19486255).","journal-title":"J Gastroenterol Hepatol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-021-00745-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-021-00745-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-021-00745-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T20:15:13Z","timestamp":1643314513000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-021-00745-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,11]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["745"],"URL":"https:\/\/doi.org\/10.1007\/s12029-021-00745-4","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,11]]},"assertion":[{"value":"24 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}